The results of the EMA survey on Brexit preparedness show that
EMA is liaising directly with the marketing authorisation holders of those 26 % of products who either did not reply to the survey or have indicated in the survey that they do not plan to submit the changes required by 30 March 2019 and have manufacturing sites in the UK only.
The Agency urges those companies who have not yet informed EMA of their Brexit preparedness plans to do so as soon as possible to mitigate any risks to the continuous supply of medicines for human and veterinary use within the EU.
EMA: Press release
> Do not hesitate, we look forward to your feedback!
Write a comment on this news.